RVNC•benzinga•
Barclays Maintains Overweight on Revance Therapeutics, Raises Price Target to $35
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on September 9, 2022 by benzinga